Arcturus Therapeutics Holdings Inc (ARCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $240.96M
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcturus Therapeutics Holdings Inc (ARCT) Earnings: Report Dates and Results
Arcturus Therapeutics Holdings (ARCT) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Arcturus Therapeutics Holdings reported EPS of -$0.26, above the -$0.60 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ARCT has an expected report date of Mar 1, 2027.
ARCT Earnings Call
The latest ARCT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ARCT beat 23, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $18.30M, up 6.7% from $17.15M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.26 | -$0.60 | -$0.92 - -$0.29 | +56.67% | Beat | N/A | 10 | 0 up, 1 down | Nov 5, 2026 | $18.30M |
| Jun 30, 2026 | -$0.84 | -$1.07 | -$1.35 - -$0.87 | +21.50% | Beat | N/A | 11 | 7 up, 3 down | Aug 6, 2026 | $2.96M |
| Mar 31, 2026 | -$0.95 | -$1.01 | -$1.38 - -$0.07 | +6.25% | Beat | N/A | 11 | 1 up, 0 down | May 7, 2026 | $2.06M |
| Dec 31, 2025 | -$1.03 | -$0.76 | -$1.27 - -$0.13 | -35.53% | Miss | N/A | 10 | N/A | Mar 3, 2026 | $7.20M |
| Sep 30, 2025 | -$0.49 | -$0.80 | -$1.66 - -$0.07 | +38.75% | Beat | N/A | 9 | 8 up, 0 down | Nov 10, 2025 | $17.15M |
| Jun 30, 2025 | -$0.34 | -$0.85 | -$1.76 - -$0.34 | +60.00% | Beat | N/A | 9 | 4 up, 1 down | Aug 11, 2025 | $28.30M |
| Mar 31, 2025 | -$0.52 | -$1.10 | -$2.10 - $0.19 | +52.73% | Beat | N/A | 8 | 0 up, 3 down | May 12, 2025 | $29.38M |
| Dec 31, 2024 | -$1.11 | -$0.49 | -$1.24 - $0.59 | -124.56% | Miss | N/A | 9 | 1 up, 0 down | Mar 6, 2025 | $22.77M |
| Sep 30, 2024 | -$0.26 | -$1.02 | -$1.85 - -$0.15 | +74.51% | Beat | N/A | 11 | 0 up, 0 down | Nov 7, 2024 | $41.67M |
| Jun 30, 2024 | -$0.64 | -$1.57 | -$2.11 - -$1.02 | +59.24% | Beat | N/A | 7 | 0 up, 0 down | Aug 5, 2024 | $49.86M |
| Mar 31, 2024 | -$1.00 | -$1.14 | -$1.71 - -$0.84 | +12.28% | Beat | -258.7% | 8 | 0 up, 0 down | May 8, 2024 | $38.01M |
| Dec 31, 2023 | -$0.32 | -$0.99 | -$2.18 - $1.84 | +67.68% | Beat | -107.2% | 10 | 0 up, 0 down | Mar 7, 2024 | $30.86M |
| Sep 30, 2023 | -$0.61 | -$1.63 | -$2.67 - -$0.59 | +62.58% | Beat | N/A | 9 | 0 up, 0 down | Nov 14, 2023 | $45.14M |
| Jun 30, 2023 | -$1.98 | -$0.42 | -$1.43 - $1.88 | -371.43% | Miss | N/A | 8 | 0 up, 0 down | Aug 7, 2023 | $10.52M |
| Mar 31, 2023 | $0.63 | $0.26 | -$2.07 - $2.92 | +142.31% | Beat | N/A | 8 | 0 up, 0 down | May 9, 2023 | $80.28M |
| Dec 31, 2022 | $4.43 | $0.98 | -$2.38 - $5.86 | +352.04% | Beat | N/A | 11 | 0 up, 0 down | Mar 28, 2023 | $160.29M |
| Sep 30, 2022 | -$1.33 | -$1.81 | -$2.41 - -$1.12 | +26.52% | Beat | N/A | 10 | 0 up, 1 down | Nov 9, 2022 | $13.37M |
| Jun 30, 2022 | -$0.82 | -$1.88 | -$2.42 - -$1.24 | +56.38% | Beat | N/A | 11 | 0 up, 0 down | Aug 9, 2022 | $27.09M |
| Mar 31, 2022 | -$1.94 | -$1.40 | -$2.43 - -$0.40 | -38.57% | Miss | N/A | 11 | 0 up, 0 down | May 9, 2022 | $5.24M |
| Dec 31, 2021 | -$1.47 | -$1.72 | -$2.22 - -$0.64 | +14.53% | Beat | N/A | 11 | N/A | Feb 28, 2022 | $5.79M |
| Sep 30, 2021 | -$2.05 | -$1.52 | -$2.59 - $0.29 | -34.87% | Miss | N/A | 12 | N/A | Nov 8, 2021 | $2.44M |
| Jun 30, 2021 | -$2.07 | -$2.25 | -$2.48 - -$1.22 | +8.00% | Beat | N/A | 14 | N/A | Aug 9, 2021 | $2.00M |
| Mar 31, 2021 | -$2.15 | -$1.23 | -$1.68 - -$0.92 | -74.80% | Miss | N/A | 13 | N/A | May 10, 2021 | $2.13M |
| Dec 31, 2020 | -$1.25 | -$0.88 | -$1.26 - -$0.38 | -42.05% | Miss | N/A | 13 | N/A | Mar 1, 2021 | $2.24M |
| Sep 30, 2020 | -$0.92 | -$0.49 | -$0.63 - -$0.40 | -87.76% | Miss | N/A | 12 | N/A | Nov 9, 2020 | $2.33M |
| Jun 30, 2020 | -$0.55 | -$0.55 | -$0.72 - -$0.33 | 0.00% | In line | N/A | 9 | N/A | Aug 10, 2020 | $2.32M |
| Mar 31, 2020 | -$0.67 | -$0.61 | -$0.82 - -$0.30 | -9.84% | Miss | N/A | 7 | N/A | May 7, 2020 | $2.65M |
| Dec 31, 2019 | -$0.76 | -$0.51 | N/A | -49.02% | Miss | N/A | N/A | N/A | Mar 11, 2020 | $2.97M |
| Sep 30, 2019 | -$0.56 | -$0.46 | N/A | -21.74% | Miss | N/A | N/A | N/A | Nov 7, 2019 | $3.32M |
| Jun 30, 2019 | -$0.07 | -$0.61 | N/A | +88.52% | Beat | N/A | N/A | N/A | Aug 15, 2019 | $10.15M |
| Mar 31, 2019 | -$0.68 | -$0.60 | -$0.68 - -$0.51 | -13.33% | Miss | N/A | 4 | N/A | May 13, 2019 | $4.35M |
| Dec 31, 2018 | -$0.08 | -$0.48 | -$0.56 - -$0.42 | +83.33% | Beat | N/A | 4 | N/A | Mar 18, 2019 | $7.58M |
| Sep 30, 2018 | -$0.42 | -$0.35 | N/A | -20.00% | Miss | N/A | N/A | N/A | Oct 1, 2018 | $3.42M |
| Jun 30, 2018 | -$0.99 | -$0.70 | -$0.70 - -$0.70 | -41.43% | Miss | N/A | 1 | N/A | Sep 28, 2018 | $2.39M |
| Mar 31, 2018 | -$1.08 | -$0.46 | N/A | -134.78% | Miss | N/A | 1 | N/A | Apr 2, 2018 | $2.37M |
| Dec 31, 2017 | -$1.08 | -$0.46 | -$0.46 - -$0.46 | -134.78% | Miss | N/A | 1 | N/A | Feb 15, 2018 | $13.00M |
| Sep 30, 2017 | -$0.70 | -$2.66 | N/A | +73.68% | Beat | N/A | N/A | N/A | Nov 9, 2017 | $3.30M |
| Jun 30, 2017 | -$0.91 | -$0.94 | N/A | +3.19% | Beat | N/A | N/A | N/A | Aug 11, 2017 | $3.76M |
| Mar 31, 2017 | -$0.91 | -$1.26 | N/A | +27.78% | Beat | N/A | N/A | N/A | May 30, 2017 | $3.84M |
| Dec 31, 2016 | -$1.54 | -$1.90 | N/A | +18.95% | Beat | N/A | N/A | N/A | Feb 15, 2017 | $20.38M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.38, after -$3.01 the year before. It was -$6.23 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.38 | N/A |
| Dec 31, 2024 | -$3.01 | N/A |
| Dec 31, 2023 | -$2.28 | -770.6% |
| Dec 31, 2022 | $0.34 | N/A |
| Dec 31, 2021 | -$7.74 | N/A |
| Dec 31, 2020 | -$3.39 | N/A |
| Dec 31, 2019 | -$2.07 | N/A |
| Dec 31, 2018 | -$2.57 | N/A |
| Dec 31, 2017 | -$3.60 | N/A |
| Dec 31, 2016 | -$6.23 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,600 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,570 | 15 | |
| 2026Q2 | Jun 30, 2026 | 5,428 | 15 | |
| 2026Q1 | Mar 31, 2026 | 5,889 | 16 | |
| 2025Q4 | Dec 31, 2025 | 7,133 | 16 | |
| 2025Q3 | Sep 30, 2025 | 6,236 | 13 | |
| 2025Q2 | Jun 30, 2025 | 5,890 | 15 | |
| 2025Q1 | Mar 31, 2025 | 5,661 | 14 | |
| 2024Q4 | Dec 31, 2024 | 6,604 | 15 |
2026Q3 Earnings Call
Opening remarks
Neda Safarzadeh Vice President, Head of Investor Relations, Public Relations and Marketing Thank you, operator. Good afternoon, and welcome to Arcturus Therapeutics' quarterly financial update and pipeline progress call. Today's call will be led by Joe Payne, our President and CEO, and Dennis Mulroy, our Chief Financial Officer. Dr. Pad Chivukula, our CSO and COO, and Dr. Alan Cohen, our Chief Medical Officer, will join them for the Q&A session. Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by this statement. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the Risk Factors section in our most recent Form 10-K and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements. And with that, I will now turn the call over to Joe.
Joseph Payne President and CEO Thank you, Neda. Good afternoon, everyone, and thank you for joining us today. The third quarter was an important period for Arcturus as we continued to advance our key clinical programs, introduced our next-generation LUNAR 2.0 delivery platform, and expanded our pipeline of mRNA therapeutics. I'd like to begin with our liver therapeutics franchise, where we believe we are entering a new, exciting phase of development. In September, we presented encouraging Phase II data from ARCT-810 in patients with ornithine transcarbamylase, or OTC, deficiency. At the 0.3 and 0.5 milligram per kilogram dose levels, ARCT-810 demonstrated meaningful biomarker activity, reducing and/or maintaining first morning fasting ammonia within the normal range, including during increased protein intake, and reducing glutamine levels in all participants, with the 0.5 milligram per kilogram dose achieving mean glutamine concentrations within the normal range during treatment. It was generally safe and well tolerated. These results provide important clinical validation of our mRNA approach to liver therapeutics and contributed to the development of our next-generation OTC program, called ARCT-2601. ARCT-2601 is particularly significant for Arcturus because it is the first mRNA therapeutic candidate utilizing our new LUNAR 2.0 delivery technology. Nonhuman primate models have consistently demonstrated strong translational predictivity for lipid nanoparticle-formulated RNA therapeutics. This is well documented. In nonhuman primates, we can measure human ornithine transcarbamylase expression.
Frequently Asked Questions About ARCT
When is Arcturus Therapeutics Holdings's next earnings date?
Arcturus Therapeutics Holdings's next earnings report is expected for Mar 1, 2027.
Did ARCT beat earnings estimates last quarter?
Yes. Arcturus Therapeutics Holdings reported EPS of -$0.26 for the quarter ended Sep 30, 2026, above the -$0.60 estimate, a 56.67% surprise.
What EPS do analysts expect from ARCT next quarter?
The consensus EPS estimate for Arcturus Therapeutics Holdings for the quarter ending Dec 31, 2026 is -$0.92 from 15 analysts, with estimates from -$1.52 to -$0.55.
How often does ARCT beat earnings estimates?
Arcturus Therapeutics Holdings beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +9.47%.
ARCT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors